Top Markets
#1 Islamic Coin Islamic Coin +152.40%
#2 Bitway Bitway +44.09%
#3 Starpower Starpower +38.95%
#4 Wrapped STX (Velar) Wrapped STX (Velar) +32.28%
#5 aelf aelf +28.62%
#6 Pons Pons +26.42%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +23.23%
#8 SkyAI SkyAI +18.91%
#9 Ocean Protocol Ocean Protocol +17.25%
#10 Bedrock Bedrock +16.75%
Coin of the day
Islamic Coin Islamic Coin
Settings
Language
ENGLISH
Currency
USD
Theme
Ulisse Biomed S.p.A. Ulisse Biomed S.p.A.

Ulisse Biomed S.p.A.

UBM
Rank in Stocks #29599
Ulisse Biomed S.p.A. is an Italy-based biotechnology enterprise specializing in... Ulisse Biomed S.p.A. is an Italy-based biotechnology enterprise specializing in healthcare diagnostics. The company develops and markets a diverse range of innovative platforms and products designed for disease detection. Central to its offerings is the Sagitta platform, which encompasses specialized tests such as Ladymed/HPV Selfy for human papillomavirus screening, CoronaMelt for identifying SARS-CoV-2, and CoronaMelt Var for detecting and genotyping SARS-CoV-2 variants. Sagitta also provides UlisseFaster, a vital reagent used for the pre-treatment of biological samples, alongside various diagnostic tools for sexually transmitted infections and for detecting HPV associated with oropharyngeal cancers. Beyond Sagitta, Ulisse Biomed boasts the NanoHybrid platform, an advanced multi-modal biomolecule system that utilizes DNA/PNA technology to directly identify specific antibodies and protein analytes from serum or whole blood samples. Its portfolio is further enhanced by the Aptavir platform, dedicated to the development and manufacturing of synthetic nucleic acid molecules aimed at curtailing the infectiousness of pathogens. Established in 2015, Ulisse Biomed S.p.A. operates from its headquarters in Udine, Italy.
Share Price
$0.93739396
Last synced: 2026-01-08
Market Cap
$20.44M
Change (1 day)
0.60%
Change (1 year)
-6.88%
Country
IT
Trade Ulisse Biomed S.p.A. (UBM)

Category

Healthcare
Revenue for Ulisse Biomed S.p.A. (UBM)
Revenue in Aug 2026 TTM: 0
According to Ulisse Biomed S.p.A. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Ulisse Biomed S.p.A. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR